• Oric Pharmaceuticals entered a clinical trial collaboration and supply agreement with Bayer for the Himalayas-1 Phase 3 trial in mCRPC.
• Bayer will supply Nubeqa (darolutamide) at no cost for use with rinzimetostat in the study.
• Oric will sponsor and run the trial; Bayer receives no license, option, or rights to rinzimetostat.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607141605PRIMZONEFULLFEED9761550) on July 14, 2026, and is solely responsible for the information contained therein.